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Abstract
Background: Glutamate (Glu) and c-aminobutyric acid (GABA) transporters play important roles in regulating neuronal
activity. Glu is removed from the extracellular space dominantly by glial transporters. In contrast, GABA is mainly taken up
by neurons. However, the glial GABA transporter subtypes share their localization with the Glu transporters and their
expression is confined to the same subpopulation of astrocytes, raising the possibility of cooperation between Glu and
GABA transport processes.
Methodology/Principal Findings: Here we used diverse biological models both in vitro and in vivo to explore the interplay
between these processes. We found that removal of Glu by astrocytic transporters triggers an elevation in the extracellular
level of GABA. This coupling between excitatory and inhibitory signaling was found to be independent of Glu receptor-
mediated depolarization, external presence of Ca
2+ and glutamate decarboxylase activity. It was abolished in the presence
of non-transportable blockers of glial Glu or GABA transporters, suggesting that the concerted action of these transporters
underlies the process.
Conclusions/Significance: Our results suggest that activation of Glu transporters results in GABA release through reversal of
glial GABA transporters. This transporter-mediated interplay represents a direct link between inhibitory and excitatory
neurotransmission and may function as a negative feedback combating intense excitation in pathological conditions such
as epilepsy or ischemia.
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Introduction
Maintenance of the balance between c-aminobutyric acid
(GABA) mediated inhibition and L-glutamate (Glu) mediated
excitation is of crucial importance under normal and pathological
conditions in the brain. Although operationally independent, the
biochemically integrated GABAergic and glutamatergic neurotrans-
mitter systems do interplay at cellular and sub-cellular levels [1–6].
The steady control over the extracellular concentrations of Glu and
GABA is crucial for cell viability. This task is performed by Glu and
GABA transporters that remove the neurotransmitters from the
extracellular space utilizing the downhill transport of Na
+. Glu
transporters (EAATs) are predominantly localized to astrocytes [7]
near the synaptic cleft [8]. Therefore proper function of EAATs is
essential and represents a critical component in the neuroprotective
role that astrocytes offer to neurons [9]. In contrast to Glu, GABA is
predominantly taken up by neurons through the GABA transporter
subtype 1 (GAT-1). Due to the prevalence of neuronal GABA
uptake, GAT-1 used to be in the focus of transporter research for
decades. As a consequence, little is known about the role of GAT
subtypes localized to glial cells (GAT-2, GAT-3) despite their
capability to markedly influence neuronal excitability [10] and the
therapeutic potential of GAT-3 up-regulation in epilepsy [11,12].
In the present study, we explore the transport properties of glial
Glu and GABA transporter subtypes and the role they might play
in establishing the crosstalk between glutamatergic and GABAergic
neurotransmissions. Applying diverse biological models at different
levels of complexity in combination with different analytical,
pharmacological and anatomical approaches, we demonstrate the
existence of a previously unrecognized mechanism through which
astrocytes exchange extracellular Glu for GABA by a concerted
action of glial Glu and GABA transporters.
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Interplay between glial Glu and GABA transport
processes in vitro
We explored the potential interplay between glial Glu and GABA
transport processes in the presence of a specific [13,14,15], non-
transportable blocker of GAT-1, 1,2,5,6-tetrahydro-1-[2-[[(diphenyl-
methylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid (NNC-711) to
pharmacologically isolate GAT-2/3 transporter function. Strikingly,
selectiveblockade of thedominantGABAtransportersubtype,GAT-
1 by NNC-711 revealed the existence of a Glu-induced inhibition of
[
3H]GABA uptake into native plasma membrane vesicles (NPMV),
isolated from rat cerebral cortex. Preincubation of vesicles with Glu
for 10 minutes resulted in 52% inhibition of GABA uptake
(Figure 1A). Besides Glu, other EAAT substrates (t-PDC, L-Asp, D-
Asp, D-Glu, cysteic acid), but not the non-transportable inhibitors
Figure 1. Cytosolic GABA level as determined by [
3H]GABA uptake in the presence of 100 mM NNC-711. (A) Inhibition of [
3H]GABA uptake
following 10 min preincubation with Glu in rat cerebrocortical NPMV fraction (n=7). IC50 value for Glu: 11.060.1 mM. (B) Inhibition of [
3H]GABA uptake
following 10 min preincubation with different EAAT substrates and inhibitors in rat cerebrocortical NPMV fraction (n=3–6). (C and D) Decreased intracellular
GABA level following Glu (C) or t-PDC (D) application in rat and human NPMVs (gray), from acute rat hippocampal slice (empty bar, n=7) and from neuronal
culture from mouse neocortex (striped bar, n=4). Abbreviations used for brain regions: rat cerebrocortical neocortex (rNCTX, n=6), rat hippocampus( r H C ,
n=3), human hippocampus (hHC, n=6), human cortical gray matter (hCGM, n=6), human cortical white matter (hCWM, n=6), human spinal cord white
matter (hSC, n=6), human choroid plexus (hCP, n=6), human corpus callosum (hCC, n=6). All drug applications significantly differ from the control (P,0.01).
(E) Intracellular [
3H]GABA level in the absence and presence of 100 mM NNC-711 during application of Glu (100 mM) or t-PDC (100 mM) in NPMV fractions from
human cortical gray matter (hCGM, n=6), human cortical white matter (hCWM, n=6) and human spinal cord white matter (hSC, n=6). Asterisks: P,0.05.
doi:10.1371/journal.pone.0007153.g001
Glu-GABA Exchange
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(TBOA) were also able to affect GABA transport in the rat cortical
NPMV (Figure 1B). Furthermore, amino acids (L-Leu, D-Leu, L-Ser,
D-Ser), substrates of GABA transporter homologues (serotonin,
dopamine), an intermediate of the GABA shunt (succinate) and an
EAAT2 inducer b-lactam antibiotics (penicillin) did not affect GABA
transport (IC50.1 mM). It is noteworthy that we did not observe an
altered Glu uptake following GABA application either in control
conditions or in the presence of NNC-711 and/or TBOA in rat
cerebrocortical NPMV fractions (data not shown).
To explore the presence of EAAT mediated [
3H]GABA uptake
inhibition, we studied NPMVs from different brain areas. In human
brain tissue samples both Glu (Figure 1C) and t-PDC (Figure 1D)
were able to inhibit [
3H]GABA uptake in all investigated areas
including hippocampus, cortex, cortical gray and white matter,
spinal cord white matter, choroid plexus and corpus callosum in
different mammalian species (rat, mouse and human) as well as at
different levels of complexity such as in brain tissue homogenates
(NPMV), in isolated slices and in primary neuronal cultures that do
express EAAT1/2 [16]. Notably, in brain regions with high glial
content (cortical white matter, spinal cord white matter) Glu and t-
PDC did inhibit [
3H]GABA uptake even in the absence of NNC-
711 (Figure 1E). Most of these experiments aimed to characterize
the molecular parameters of the interplay between Glu and GABA
transport processes were performed on NPMV fractions. However,
the results are expected to be valid in isolated brain tissue slices as
well because both Glu and t-PDC were found to be equally potent
inhibitors of GABA uptake in rat hippocampal NPMVs and in
freshly isolated (acute) rat hippocampal slices (Figure 1C, D). These
results clearly demonstrate the existence of a Glu-induced GABA
transport process throughout the brain.
Interplay between glial Glu and GABA transport
processes in vivo
We tested whether the activation of EAATs alters GABA
transport in vivo. According to the in vitro results, application of the
Glu transporter substrate t-PDC resulted in an increased
extracellular GABA level ([GABA]o) in the rat hippocampus in
vivo (Figure 2). The substantial increase of the tightly controlled
[GABA]o [17] following t-PDC administration was comparable to
that evoked by GAT-1 blockade (Figure 2), predicting a significant
consequence of the interplay between the Glu and GABA
transport processes. To demonstrate that increase in extracellular
GABA level is due to specific t-PDC effect, we measured the level
of arginine as a reference amino acid. Arginine level did not
change significantly during either NNC-711 or t-PDC application.
It is worth noting that the extracellular concentration of applied
drugs is lower than the concentration set in the microdialysis
probe. Based on substance recovery curves [18], we estimate the
extracellular concentration of NNC-711 and t-PDC to be 100 mM
and 400 mM, respectively. Therefore the presence of the Glu-
dependent GABA transport process is not restricted to in vitro
model systems, it is present in the in vivo functional brain.
Glu transporter activation induces GABA release
In all the above experiments, intra- or extracellular GABA
content was determined. Apparent inhibition of GABA uptake can
be the result of either inhibited uptake or enhanced release. To
decide between these possibilities, two different experimental
approaches were applied. In the steady-state experiment, rat cortex
NPMVs were preloaded with [
3H]GABA and extra- and intracel-
lular [
3H]GABA contents were determined after 10 min incubation
with different concentrations of [
14C]Glu. Glu application dose-
dependently triggered the release of the preloaded GABA
(Figure 3A). In the superfusion experiment, acute rat hippocampal
slices were preloaded with [
3H]GABA and the extracellular GABA
content was recorded in a microvolume superfusion system. The
extracellular [
3H]GABA level elevated to an average 149614% of
pre-stimulus control following application of 100 mM Glu
(Figure 3B). It is noteworthy that although this Glu concentration
is much higher than the steady state extracellular [Glu], it reflects
the concentration sensed by EAATs. After synaptic release, the
concentration of Glu in the synaptic cleft may elevate to 1–5 mM
[19]. Since EAATs are located near the release site
8, they are
exposed to relatively high Glu concentrations (160–190 mM) [20].
In both experiments, Glu application directly evoked the release of
the preloaded labeled GABA, demonstrating that the Glu-
dependent GABA transport is a GABA release process.
Glu-induced GABA release cannot be blocked by Glu
receptor antagonists
To investigate the possibility whether GABA release is due to
glutamatergic stimulation of inhibitory neurons, Glu receptor
antagonists were applied. NMDA (DL-2-amino-5-phosphonopen-
tanoic acid: DL-AP5, 50 mM), AMPA/kainate (6-cyano-7-nitro-
quinoxaline-2,3-dione: CNQX, 10 mM) and metabotropic ((S)-a-
methyl-4-carboxyphenylglycine: (S)-MCPG, 500 mM) Glu recep-
tor antagonists partially inhibited the Glu-induced GABA release
(Figure 4A). However, 58% of average [GABA]o increase
remained in the presence of Glu receptor antagonists.
In the rat cortical NPMV fraction, application of Glu receptor
antagonists did not alter the effect of Glu on GABA transport
(Figure 4B). In addition, blockade of the chloride influx through
GABAA receptors by the antagonist (1S,9R)-bicuculline methio-
dide and GABAB receptor-mediated inhibition of GABA release
by the agonist (R)-baclofen did not modulate the effect of Glu on
the cytosolic GABA level (n=4; P=0.86; data not shown).
These data conclusively suggest that Glu-induced GABA release
is not triggered by Glu receptor mediated depolarization.
Glu-induced GABA release is independent of extracellular
Ca
2+
Major mechanisms for neurotransmitter release are Ca
2+-
dependent vesicular release and reversal of plasma membrane
Figure 2. Elevation of [GABA]o in the rat hippocampus in vivo
following NNC-711 and t-PDC administration (n=10, P=0.019
(t-PDC vs. NNC-711), NNC-711: 160618, t-PDC: 233633, % of
control). [Arginine]o was used as a control for possible non-specific
release (n=10, P=0.6, NNC-711: 100625, t-PDC: 94632, % of control).
doi:10.1371/journal.pone.0007153.g002
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release is not due to glutamatergic stimulation of inhibitory
neurons, we examined GABA efflux from rat hippocampal slices
in high-[Mg
2+]/low-[Ca
2+] media (Figure 4C) and in the presence
of 50 mMC d
2+ salt in the superfusion (n=3; P=0.82; 143610%
of pre-stimulus control, data not shown). We also determined
GABA uptake in rat cortical NPMV under low-[Ca
2+] conditions
(Figure 4D). All these experimental approaches indicated that the
Figure 3. Glu induces GABA release (A) Glu uptake decreases cytosolic GABA level as determined by [
3H]GABA release from NPMV
vesicles preloaded with [
3H]GABA (n=3). IC50 value for Glu: 13.161.6 mM. (B) Elevation of [GABA]o in acute rat hippocampal slices during
application of 100 mM Glu (n=6; 149614% of pre-stimulus control).
doi:10.1371/journal.pone.0007153.g003
Figure 4. Glu-induced GABA release is not mediated by vesicular release. (A) Elevation of [GABA]o in acute rat hippocampal slices in control
conditions (n=6) and in the presence of glutamate receptor antagonists (n=7; P=0.014; 128.5613.4% of pre-stimulus control). (B) Cytosolic GABA
level as determined by [
3H]GABA uptake in the presence of 100 mM NNC-711 and Glu receptor antagonists in rat cerebrocortical NPMV fractions
(n=4; P=0.82) (C) Elevation of [GABA]o in acute rat hippocampal slices in control conditions (n=6) and in low-[Ca
2+]/high-[Mg
2+] buffer (n=5;
P=0.91; 148.3615.5% of pre-stimulus control). (D) Cytosolic GABA level as determined by [
3H]GABA uptake in the presence of 100 mM NNC-711 in
low-[Ca
2+] buffer in rat cerebrocortical NPMV fractions (n=3; P=0.49). Low-[Ca
2+] buffer contained 145 mM NaCl, 5 mM KCl, 20 mM MgCl2,1 0m M
glucose and 20 mM HEPES (pH 7.5).
doi:10.1371/journal.pone.0007153.g004
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2+-
independent, therefore it is not a vesicular release.
Glu-induced GABA release is independent of Glu
decarboxylase
Previous studies reported a receptor-independent, metabolic
pathway through which extracellular Glu may elevate [GABA]o
[4,5,22]. This mechanism is thought to involve neuronal uptake of
Glu through EAAT3, metabolic conversion to GABA by Glu
decarboxylase (GAD) and release of this newly synthesized GABA.
To decide whether this mechanism contributes to the Glu-induced
GABA release, the source of GABA in rat cortical NPMV fraction
was determined by two dimensional NMR methods following
[
13C]Glu administration. It was found that ,5% of extracellularly
applied [
13C]Glu was converted to [
13C]GABA and released into
the extracellular space (Figure 5A). Although in situ formation of
GABA elucidates Glu-induced GABA release, it is highly unlikely
that other EAAT substrates like t-PDC and cysteic acid can
replace Glu in metabolic pathways. Therefore, an additional
mechanism should take place in action. Indeed, the [
13C]GABA
formation was completely blocked by treatment with the GAD
inhibitor semicarbazide (SCB) in rat cortical NPMV fraction
(Figure 5A). In acute hippocampal slices SCB treatment also
significantly reduced [
13C]GABA formation from [
13C]Glu (data
not shown). However, SCB treatment did not affect [
3H]GABA
release either from acute hippocampal slices (Figure 5B) or from
rat cortical NPMV fractions (Figure 5C). Since different pools of
GABA (newly synthesized vs. previously captured, respectively)
were labeled in NMR and radiotracer measurements, the relative
weights of the GAD-mediated and the GAD-independent
processes were obtained by measuring the total pool of GABA
using HPLC studies from rat cerebrocortical NPMV samples. We
found that application of 300 mM Glu increased the extracellular
GABA level by 4663% in control (n=3, P=0.003) and by
3566% in SCB-treated rats (n=3, P,.001). The moderate
decrease of [GABA]o elevation in SCB-treated rats (35% vs. 46%
in control animal) suggests that the GAD-independent mechanism
represents the major route in Glu-induced GABA release.
Localization of GAT-1 and GAT-3 in the hippocampus
To explore the specific localization of different GABA
transporter subtypes possibly involved in the Glu-induced GABA
release, we investigated the expression of GAT-1 and GAT-3 by
immunostaining (Figure 6). GAT-1 immunoreactivity was local-
ized throughout the hippocampus in puncta while in the
pyramidal cell layer labeled fibers can be followed radially along
the neuronal cell bodies. GAT-1 immunoreactivity was co-
localized with synaptophysin (Figure 6B) suggesting its presynaptic
localization. A much lower (,10% of GAT-1) density of GAT-3
immunolabeling is present in the hippocampus. GAT-3 immuno-
Figure 5. Glu-evoked GABA release is independent of glutamate decarboxylase. (A) Contour plot representations of gradient enhanced
1H/
13C heteronuclear single quantum coherence (
13C-HSQC) spectra of extracellular fluid sample from rat cerebrocortical NPMV after incubation with
[U-
13C/
15N]Glu for 30 min in control (black) and semicarbazide (SCB)-treated animal (red). GABA resonances (arrows) do not appear in the samples
from SCB-treated animal. (B) Elevation of [GABA]o in acute rat hippocampal slices in control (n=6) and SCB-treated animals (n=7; P=0.54; 145614%
of pre-stimulus control). (C) Intracellular [
3H]GABA level as determined by [
3H]GABA uptake in the presence of 100 mM NNC-711 in control condition
and in SCB-treated animals (n=3, P=0.85).
doi:10.1371/journal.pone.0007153.g005
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synaptophysin (Figure 6E) but shows a significant co-localization
with glial fibrillary acidic protein (GFAP) suggesting its presence in
astrocytes (Figure 6F).
Glu-induced GABA release is mediated by GAT-2/3
Since it was demonstrated before that Glu-induced GABA
release is not through vesicular release, it is plausible to assume
that it is mediated by reversal of GABA transporter. This
hypothesis was further supported by the pharmacological profile
of GABA uptake in rat cerebrocortical NPMV in the presence of
NNC-711 (Table 1). To confirm this assumption, GABA efflux
from rat hippocampal slices was determined in the presence of the
specific, non-transportable GAT-2/3 inhibitor 1-[2-[tris(4-meth-
oxyphenyl)methoxy]ethyl]-(S)-3-piperidinecarboxylic acid (SNAP-
5114). SNAP-5114 mostly inhibited Glu from evoking GABA
release in rat hippocampal slices (Figure 7A). The ability of Glu to
reduce cytosolic level of the specific GAT-2/3 substrate b-alanine
(Figure 7B) further reinforced the involvement of GAT-2/3.
Glu-induced GABA release requires preceding Glu uptake
The inability of non-transportable EAAT inhibitors to affect
GABA transport in the rat cortical NPMV (Figure 1B) suggested
that the translocation process through Glu transporters is required
to evoke the GABA release. To examine this possibility, the non-
transportable EAAT inhibitors, DHK and TBOA were applied to
exclude substrate transport. Inhibition of Glu transporters by
100 mM and 1000 mM TBOA resulted in a concentration
dependent inhibition of Glu-induced GABA release in hippocam-
pal slices (Figure 7C). Because EAAT blockade leads to
extracellular Glu accumulation and therefore increased activation
of Glu receptors, this finding further confirms that Glu-induced
GABA release is not due to receptor-mediated activation of
inhibitory neurons. The effect of Glu on GABA transport in rat
cerebrocortical NPMV fraction was also significantly reduced in
the presence of the selective EAAT2 blocker DHK (100 mM,
Figure 7D) and further reduced in the presence of the non-
selective EAAT1-3 blocker TBOA (Figure 7D), indicating that Glu
uptake is a prerequisite to GABA release.
Figure 6. GABA transporter subtypes double labeled with neuronal and glial markers in hippocampal sections. GAT-1 (A–C) and GAT-
3 (D–F) are labeled with green while NeuN (A, D), synaptophysin (B, E), and GFAP (C, F) are red. The yellow labeling in B and F demonstrate co-
localization of GAT-1 with synaptophysin and GAT-3 with GFAP (some colocalization sites are marked by arrows). Scale bar =50 mm.
doi:10.1371/journal.pone.0007153.g006
Table 1. GABA release following Glu application is probably
mediated by GAT-2/3. Pharmacological profile of GABA
transport in rat cerebrocortical NPMV in the presence of
100 mM NNC-711.
IC50 (mM)
GAT-1
a BGT
a GAT-2
a GAT-3
a
Rat cerebrocortical
NPMV
b
b-alanine 2920 1100 66 110 2664
Taurine .1000 .1000 1270 2860 40067
Nipecotic acid 24 2350 113 159 2860.5
Hypotaurine 1010 536 52 73 2060.4
SKF89976A 0.64 7210 550 4390 37269
Betaine .1000 173 .1000 .1000 .1000
aBorden,L.A. GABA transporter heterogeneity: pharmacology and cellular
localization (1996) Neurochem Int. 4: 335–356.
bpresent study.
doi:10.1371/journal.pone.0007153.t001
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transmission
The above experiments clearly showed that activation of Glu
uptake by exogenously applied Glu fosters GABA release through
glial GAT-2/3. Next we explored whether the concentration
reached by endogenous Glu is able to activate the Glu-GABA
exchange mechanism. To specifically study the GABA release
through GAT-2/3 we applied 100 mM SNAP-5114 to block this
release route in control conditions without exogenously added
Glu. Blockade of GAT-2/3 did not decrease the [
3H]GABA
release from the labeled cytosolic pool (Figure 7E), indicating that
GAT-2/3 mediated GABA release does not contribute to
[GABA]o. However, increasing synaptic Glu release by applying
nominally Mg
2+-free medium [23,24] revealed a significant
contribution of the Glu-GABA exchange mechanism to the
overall GABA release (Figure 7E). In nominally Mg
2+-free ACSF,
application of 100 mM SNAP-5114 reduced the [
3H]GABA
release by 10% on average compared to the pre-application
period (Figure 7E), suggesting that the Glu-GABA exchange
mechanism can emerge simultaneously with the network activity.
Discussion
The principal finding of this study is that the uptake of Glu is
coupled to the subsequent reversal of the glial GABA transporters
bringing about an elevation in the level of extracellular GABA. We
were thus able to show, for the first time, [GABA]o signals
resulting from glial Glu uptake. We demonstrated the presence of
this Glu-GABA exchange mechanism in vivo in the rat hippocam-
pus and in vitro by measurements of GABA uptake and release in
rat brain slices, in cultured mouse neurons as well as in rat or
Figure 7. Glu-induced GABA release requires the concerted action of Glu and GABA transporters. (A) Elevation of [GABA]o in acute rat
hippocampal slices in control conditions (n=6) and in the presence of the specific GAT-2/3 blocker, SNAP-5114 (n=4, P,0.001; 10964% of pre-
stimulus control). (B) Cytosolic b-alanine level as determined by [
3H]b-alanine uptake in rat cerebrocortical NPMV fraction (n=3). (C) Elevation of
[GABA]o in acute rat hippocampal slices in control conditions (n=6) and in the presence of the Glu transporter blocker, TBOA (100 mM: n=4,
P,0.001; 123610% of pre-stimulus control, 1000 mM: n=4, P,0.001; 10961% of pre-stimulus control). (D) Cytosolic GABA level as determined by
[
3H]GABA uptake in the presence of 100 mM NNC-711 and Glu transporter blockers in rat cerebrocortical NPMV fraction (n=3; P,0.001 for both DHK
and TBOA). (E) Alteration of [GABA]o in acute rat hippocampal slices in normal ACSF (control, n=5, 10066% of pre-application control) and in
nominally Mg
2+-free ACSF (low-[Mg
2+], n=5, P,0.001; 9064% of pre-application control) during blockade of GAT-2/3 by the specific, non-
transportable inhibitor SNAP-5114.
doi:10.1371/journal.pone.0007153.g007
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cortical gray and white matter, spinal cord, corpus callosum,
choroid plexus and the hippocampus. We found that all Glu
transporter substrates examined, but not non-transportable
inhibitors were able to evoke GABA release.
GABA release is triggered by Glu transporter and not by
Glu receptor activation
We presented several lines of evidence to support that Glu-
induced GABA release does not involve Glu receptor-mediated
depolarization. The fact that Glu-induced GABA release is
partially inhibited in the presence of Glu receptor antagonists in
the radiotracer release experiments apparently imply that the
underlying mechanism does involve the activation of Glu
receptors. However, we have demonstrated that GABA release
was unaffected by applying low-[Ca
2+] conditions or by the
presence of Cd
2+, indicating that GABA is released by reversal of
GABA transporters and not by vesicular release. Our explanation
for the partial inhibition of Glu-induced GABA release by Glu
receptor antagonists is that Glu application both induces the
GABA release through the mechanism described here and also
keeps the neurons in an enhanced activation state. The enhanced
activation leads to increased Glu release and subsequently
increased activation of the EAATs. By adding Glu receptor
antagonists, the neuronal activity was reduced resulting in a
smaller effect of EAAT activation on GABA release. The lack of
Glu receptor mediated component in the Glu-induced GABA
release is further confirmed by the fact that GABA release can be
excluded by EAAT blockade. In case of substantial Glu receptor
contribution to the mechanism, EAAT blockade should not have
been complete, because the increasing extracellular Glu level and
subsequent intensification of Glu receptor currents should have
overwhelmed the blockade of the EAATs. Therefore we propose
that GABA release is prominently induced by EAAT activation.
The lack of Glu receptor contribution to the evoked GABA
release may be due to the localization of GAT-2/3 transporters. In
the hippocampus, their expression is confined to protoplasmic
astrocytes [25]. This astrocyte subpopulation expresses Glu
transporters, but does not express Glu receptors [26]. The lack
of Glu receptor expression on GAT-2/3 expressing protoplasmic
astrocytes does explain the lack of Glu receptor contribution to the
glial GABA release.
Proposed model of Glu-induced GABA release
To explain these findings, we propose a model for the
mechanism underlying extracellular Glu-GABA exchange (Fig. 8).
This model takes advantage of the phenomenon that GABA
release can only be evoked by transportable EAAT substrates,
recognizing the Glu translocation process itself as a prerequisite in
inducing the release of GABA. Removal of Glu from the
extracellular space is predominantly mediated by glial EAAT1
and EAAT2 and is coupled [27] to co-transport of 3 Na
+/1 H
+
and counter-transport of 1 K
+, resulting in subsequent disruption
of the resting electrochemical potential. Because GABA transport
is also driven by Na
+ gradient, the increased intracellular [Na
+]
may be capable of reversing GABA transporters. It is known from
both theoretical [28] and experimental [29,30] studies that GABA
transporters operate close to their equilibrium potentials, therefore
small perturbations in the extracellular or intracellular concentra-
tions of GABA, Na
+ or Cl
2 may lead to reversal of GATs [30]. By
the reversed action of glial GAT-2/3, intracellularly available
GABA in astrocytes [31–34] can be released into the extracellular
space. Since GAT-2/3 transporters are located outside the synapse
[35], the released GABA is likely to activate the extrasynaptic
GABA receptors located on dendrites [36] and may contribute to
the tonic inhibition of neurons.
Consequences of Glu-induced GABA release
The coupling between substrate activation of EAATs and
subsequent GABA release implies that transportable and non-
transportable inhibitors of Glu transport should have differential
effects on neuronal viability. Indeed, this distinction was observed
in several cases. In contrast to the non-transportable blocker
DHK, the substrate t-PDC did not evoke neuronal damage in vivo
even in very high concentration (25–100 mM), despite the fact
that extracellular [Glu] elevation was similar [37] or even higher
[38,39] after t-PDC application than following DHK treatment.
Also, in vivo administration of TBOA in the hippocampus was
demonstrated to induce neuronal damage in the CA1 and the
dentate gyrus, while t-PDC application did not produce cell death
[40]. Beyond the primary benefit of turning excitation into
inhibition, the Glu-GABA exchange also helps in the recovery of
the transmembrane Na
+ gradient without using ATP, thus
profiting energy from neuroprotection. The maintenance of the
Na
+ homeostasis may in turn facilitate Glu uptake, allowing a
substrate-induced increase of Glu transport activity without the
need for protein synthesis [41].
Physiological/pathophysiological role of Glu uptake-
coupled GABA release
We have showed that GAT-2/3 mediated GABA release does
not contribute to the [GABA]o under normal, physiological
conditions, but significantly emerges in low-[Mg
2+] medium which
Figure 8. Schematic representation of the hypothesized Glu-
GABA exchange mechanism. Glial uptake of Glu is coupled to the
release of GABA. The mechanism supposes that the Na
+ that is
cotransported with Glu initiates GAT-2/3 transporter reversal.
doi:10.1371/journal.pone.0007153.g008
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imply that the Glu-GABA exchange is primarily a pathophysio-
logical mechanism. However, it is worth noting that network
activity in in vitro brain slices is significantly reduced when
compared to in vivo data [43,44]. We measured average firing rate
of hippocampal pyramidal cells of 0.6 Hz in normal ACSF and
3.5 Hz in low-[Mg
2+] medium [43]. The latter is more
comparable to in vivo firing rate of 3–5 Hz [44], suggesting that
in vivo network activity may be sufficient to drive the Glu-GABA
exchange. Nevertheless, the Glu-GABA exchange mechanism has
the potential to limit Glu increase and/or counterbalance its
effects under pathophysiological condition. The functional role of
the Glu-GABA exchange may also be highlighted by the marked
increase of GAT-3 expression in astrocytes, in the hippocampi of
patients with temporal lobe epilepsy [25]. The dysfunction of the
mechanism may also lie behind the impairment of the cross-talk
between excitatory and inhibitory transport processes in temporal-
lobe epilepsy [45,46]. Treatments that target a mechanism which
is up-regulated in situ in pathological conditions can represent an
ideal strategy in drug development. As an example, the
antiepileptic drugs clobazam and levetiracetam have been shown
to up-regulate GAT-3 expression in the hippocampus [11,12],
highlighting the role of glia and glial transporters in maintaining
the balance between inhibition and excitation [47]. We envision
that the discovery of the glial Glu-GABA exchange will support
the development of new pathomechanism-specific treatments for
pathological conditions characterized by intense excitation, such
as epilepsy or ischemia.
Materials and Methods
Animals were kept and used in accordance with the European
Council Directive of 24 November 1986 (86/609/EEC), the
Hungarian Animal Act, 1998. All experiments involving animals
were done by the approval of the Animal Testing Committee of
the Chemical Research Center, Hungarian Academy of Sciences
and by the approval of the Ministry of Agriculture and Rural
Development, Hungary. All efforts were made to reduce animal
suffering and the number of animals used.
The human brains were obtained from the Lenhossek Human
Brain Program, Human Brain Tissue Bank, Budapest. Brains were
taken from persons who had died without any known neurode-
generative diseases. The collection of brains and the microdissec-
tion of the brain samples for research have been performed by the
approval of the Regional Committee of Science and Research
Ethics of the Semmelweis University, Budapest (TUKEB:32/92)
and the Ethics Committee of the Ministry of Health, Hungary,
2002 according to the principles expressed in the Declaration of
Helsinki. Tissues were collected only after a family member gave
informed (written) consent.
Buffers
Buffers contained in mM; HEPES buffer: 145 NaCl, 5 KCl, 1
CaCl2, 1 MgCl2, 10 glucose and 20 HEPES (pH 7.5); ACSF: 129
NaCl, 3 KCl, 1.6 CaCl2, 1.8 MgSO4, 1.25 NaH2PO4,2 1
NaHCO3, 10 glucose (pH 7.4); nominally Mg
2+-free ACSF was
prepared as control ACSF with no added Mg
2+ (based on the
Mg
2+ contamination of the Ca
2+ salts, we estimated the Mg
2+
concentration of this buffer to be ,1 mM).
Slice preparation
Transverse, 400 mm thick hippocampal-entorhinal slices from
11–18 day old Wistar rats (Toxicoop, Budapest, Hungary) were
prepared in modified artificial cerebrospinal fluid (75 mM sucrose,
87 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 7 mM MgSO4,
0.5 mM CaCl2, 25 mM NaHCO3, 25 mM glucose, continuously
bubbled with 95% O2 +5% CO2 gas mixture) at 4uC, as described
before [48]. Slices were incubated in an interface-type chamber
that for 1 hour at 37uC (followed by incubation at room
temperature) before performing the experiments. In experiments
where [Mg
2+] was lowered, slices were incubated in ACSF
containing ,100 mMM g
2+ and transferred to nominally Mg
2+
free medium in the recording chamber 20–30 minutes before the
start of the electrophysiological recording.
[
3H]GABA and [
3H]b-alanine exchange in native plasma
membrane vesicle (NPMV) fractions
Cerebral cortices of 4–6 weeks old male Wistar rats (Toxicoop,
Hungary) and frozen human brain tissue samples (Hungarian
Brain Tissue Bank, Budapest) were used to prepare NPMV
fractions, that contain numerous membrane vesicles of different
sizes and shapes, a few intact synaptosomes and free mitochondria
[49]. Uptake studies were performed as follows: aliquots of NPMV
fractions in HEPES buffer were preincubated with test compounds
in the presence of NNC-711 (100 mM, Tocris) at 30uC for 10 min.
Application of NNC-711 resulted in 8663% reduction of the
[
3H]GABA uptake (n=51). Afterward, preincubated solution was
incubated with [
3H]GABA (10 nM, Amersham) and GABA
(90 nM, Sigma) for 1 min. In case of [
3H]b-alanine uptake,
incubation solution contained 100 nM [
3H]b-alanine (Amersham)
and 900 nM b-alanine (Sigma). After the incubation, samples were
immediately filtered through glass fiber filters and washed twice
with ice-cold HEPES buffer. The [
3H]GABA level inside the
plasma membrane vesicles was determined by liquid scintillation
method. Although this method is generally used to measure GABA
uptake, we applied it to follow GABA release due to the simplicity
and reliability of the assay. We also determined GABA release by
preloading [
3H]GABA into NPMV vesicles and measuring the
[
3H]GABA level in the intracellular and extracellular milieu. The
determined IC50 for Glu determined by the two assays did not
differ significantly. Non-specific uptake was determined in the
presence of 1 mM guvacine. The radioactivity of samples was
counted in HiSafe 3 (Perkin Elmer) scintillation mixture.
[
3H]GABA exchange in neuronal cell cultures
Cortical neurons obtained from dissociated neocortex of 15 day
old mouse embryos were cultured for 7 days as described by Hertz
et al. [41]. Cytosine arabinoside (20 mM) was added to the cultures
after 48 hours in vitro [50]. On the day of the experiment, the cell
cultures were pre-incubated for 30 min with the test compound in
physiologically balanced salt solution (137 mM NaCl, 2.7 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 4.3 mM Na2HPO4, 1.4 mM
KH2PO4, 6.5 mM glucose, pH 7.4) in the presence of 100 mM
NNC-711, followed by the addition of [
3H]GABA and GABA to a
final concentration of 3 mCi/ml and 0.5 mM, respectively. After
3 min, the cells were washed, solubilized and used for measure-
ments of radioactivity and protein contents [51].
[
3H]GABA exchange in rat hippocampal slices
Rat hippocampal slices were placed on the bottom of 6 ml
sample holder tubes. 400 ml of solutions containing 10 nM
[
3H]GABA (Amersham) and 90 nM GABA (Sigma) were added
onto the slices and incubated at 30uC for 1 min. Uptake was
terminated by quenching with 4 ml ice-cold guvacine (1 mM,
Sigma) solution and the slices were washed twice with ice-cold
HEPES buffer. Afterwards, slices were vortexed in 400 ml HEPES
buffer containing 5% Na-dodecylsulfate. Non-specific uptake was
Glu-GABA Exchange
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of samples was counted in HiSafe 3 scintillation mixture.
In vivo microdialysis and HPLC amino acid detection
Male Wistar rats (300–400 g) were anaesthetized with halo-
thane (1% in air) and microdialysis probes were implanted into the
ventral hippocampus (A: 25.0, L: 5.0, V: 28.0) as described
previously [52]. To minimize tissue damage, the final position of
the probes was reached slowly, in not less than 20 min. Perfusion
of artificial cerebrospinal fluid, containing 144 mM NaCl, 3 mM
KCl, 1 mM MgCl2, 2 mM CaCl2 (pH 7.4), was performed at a
rate of 1 ml/min. The dialysate samples during 20 min were stored
at 220uC. To establish the background amino acid concentration,
each experiment started with the collection of three control
samples with ,10% variation. NNC-711 was applied bilaterally
for 60 min followed by the simultaneous application of t-PDC and
NNC-711 for 60 min. Concentration of amino acids was
measured by pre-column derivatization of primary amino acids
with orthophthalaldehyde (OPA, Sigma). Derivatization was
performed at pH 10.4 in the presence of mercaptoethanol.
OPA-derivatized amino acids were detected with fluorescence
detector excitation wavelength 340 nm and emission wavelength
440 nm. Because of the instability of OPA derivatives, the HPLC
technique was automated on an HP 1100 series system. Amino
acids were separated on HP Hypersyl ODS reversed-phase
columns (20062.1 mm) filled with 5 mm C-18 spherical packing
material. Eluent A was 0.1 M phosphate buffer containing 0.5%
(vol/vol) tetrahydrofuran (Merck), pH 5.6, while eluent B
contained 70% acetonitrile (Merck) in eluent A, pH 5.6. The
gradient profile was: 12% B at 0 min, 23% B at 9 min, 36% B at
18 min, 100% B at 20 min, 100% B at 25 min and 12% B at
30 min. The column equilibration time was 8 min. External
standards of 10 mM amino acids were injected after every 20
samples. Chromatograms were evaluated with HP Chem-Station
software. Concentration of GABA measured in dialysate samples
collected during drug applications were related to averaged GABA
concentration of control samples collected for an hour prior to
drug application and were given as percent changes. The basal
GABA concentration of the dialysate samples was found to be
0.07560.02 mM in the hippocampus of rats in accordance with
data from other studies (0.06960.013 mM) [53].
[
3H]GABA efflux from acute rat hippocampal slices
Radiolabeling of 400 mm thick acute slices was conducted in
200 ml of ACSF in a glass tube. This ACSF contained [
3H]GABA
(100 nM, Amersham) with 900 nM unlabeled GABA, and GABA
transaminase (GABA-T) inhibitors vigabatrin (1 mM, Tocris) or
gabaculine (250 mM, Tocris). To preferentially label the cytosolic
over the vesicular pools, incubation of slices at 30uC lasted for
10 min [54]. Slices were washed with fresh ACSF containing
GABA-T inhibitors, thereafter placed in a custom-built closed
micro-volume (50 ml) chamber secured in a water bath thermo-
stated at 30uC [55]. Thereafter, superfusion of ACSF (30uC) with
100 mM NNC-711 (Tocris), and vigabatrin (1 mM) or gabaculine
(250 mM) at a rate of 0.5 ml/min was started. The superfusate was
collected in 0.5 ml fractions. After washing for 10 min, 10
fractions were collected to define the basal release of radioactivity
(‘pre-stimulus’). At this point, the hippocampal slice was exposed
to 100 mM Glu for a period of 10 min (‘drug application’),
followed by further 10 min of washing with ACSF (‘washout’).
Radioactivity of each 0.5 ml fraction counted in 3 ml HiSafe 3
scintillation mixture was expressed as the percentage of the actual
radioactivity content of the slice (fractional release). Fractional
release data from individual slices were normalized to a first order
exponential curve (obtained by fitting the pre-stimulus and the last
3 washout values). Normalized percent efflux data from fractions
of ‘pre-stimulus’ (1–10 min) versus ‘drug application’ (11–20 min)
periods were averaged and compared by statistical analysis.
Double immunolabeling of GAT-1 and GAT-3 with
neuronal and glial markers
Sections were immunolabeled first for GAT-1 or GAT-3 using
affinity-purified polyclonal antisera (cat. #AB1570, lot
#LV1436658 for GAT-1, and cat. #AB1574, lot #0512017869
for GAT-3, Chemicon, Temecula, CA). The epitope for the anti-
GAT-1 antiserum was the C-terminus of rat GAT-1 (aa 588–599).
The epitope for the anti-GAT-3 antiserum was the C-terminus of
rat GAT-3 (aa 607–627) coupled to keyhole limpet hemocyanin.
No cross-reactivity to the C-termini of other transmitter
transporters was detected for either antiserum (see manufacturer’s
technical data sheet). The immunostaining was performed by
using FITC-tyramide fluorescent amplification immunocytochem-
istry for GAT isoforms followed by Alexa594 labeling of the
neuronal or glial markers. Briefly, free-floating brain sections were
pretreated in phosphate buffer (pH=7.4; PB) contaning 0.5%
Triton X-100 and 3% bovine serum albumin for 1 hour. Then
they were incubated with primary antibody against GAT-1 (1:200)
or GAT-3 (1:150) in PB containing 0.5% Triton X-100, 3%
bovine serum albumin, and 0.1% sodium azide for 48 hours at
room temperature. Sections were then incubated in biotin-
conjugated donkey anti-rabbit secondary antibody at 1:500
(Jackson ImmunoResearch, West Grove, PA) for 2 hours, followed
by incubation in avidinbiotin- horseradish peroxidase complex
(ABC) at 1:300 (Vectastain ABC Elite kit, Vector, Burlingame,
CA) for 2 hours. Then sections were treated with fluorescein
isothiocyanate (FITC)-tyramide (1:8000) and 0.003% H2O2 in
Tris-HCl buffer (0.05 M, pH 8.2) for 8 minutes. After washing,
the sections were incubated overnight in either of the following
mouse monoclonal primary antibodies: anti-glial fibrillary acidic
protein, a marker of astrocytes (GFAP; 1:250; cat. #sc-33673,
Santa Cruz Biotechnology, Santa Cruz, CA), NeuN, a marker of
neuronal cell bodies (1:250; cat. #MAB377, lot #25070259,
Chemicon), or anti-synaptophysin, a marker of presynaptic
terminals (1:100; cat. #M0776, CakoCytomation, Glostrup,
Denmark). After incubation in the primary antibodies, sections
were incubated in Alexa 594 donkey anti-mouse secondary
antibody (1:400; Molecular Probes) for 2 hours and mounted on
positively charged slides (Superfrost Plus, Fisher Scientific, Fair
Lawn, NJ), and coverslipped in antifade medium (Prolong
Antifade Kit, Molecular Probes, Eugene, OR).
Sections were examined by using an Olympus BX60 light
microscope also equipped with fluorescent epiillumination. Images
were captured at 2,04862,048 pixel resolution with a SPOT
Xplorer digital CCD camera (Diagnostic Instruments, Sterling
Heights, MI) by using 4–40X objectives. Confocal images were
acquired at 1,02461,024 pixel resolution with a Nikon Eclipse
E800 confocal microscope equipped with a BioRad Radiance
2100 Laser Scanning System by using 20–40X objectives at optical
thicknesses of 1–5 mm. Contrast and sharpness of the images were
adjusted by using the levels and sharpness commands in Adobe
Photoshop CS 8.0 (Adobe Systems, San Jose, CA). Full resolution
was maintained until the photomicrographs were cropped and
assembled for printing, at which point images were adjusted to a
resolution of 300 dpi.
NMR studies
NPMV samples for NMR experiments were prepared as
described before [49]. NPMV fractions from the whole cortex
Glu-GABA Exchange
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[
13C]Glu and were incubated at 30uC for 30 min. The
homogenate was then centrifuged at 3500 g for 15 min. The
supernatant (extracellular fraction) was stored and the pellet
(intracellular fraction) was suspended in 1 ml HEPES buffer and
frozen (280uC) and thawed 3 times. In the NMR experiments on
brain slices, 13 hippocampal slices were put in a 2 ml centrifuge
tube and the ACSF was replaced with 1 ml ACSF containing
300 mM[
13C]Glu. The slices were incubated at 37uC for 30 min.
Afterwards, the samples were frozen (280uC) and thawed 3 times.
NMR experiments were carried out at 30uCo naVarian NMR
SYSTEM (600 MHz for
1H) four-channel spectrometer using a
5 mm indirect detection triple resonance (
1H
13C
15N) z-axis
gradient probe. Samples (200 ml) were placed into 5 mm Shigemi
NMR tubes. Gradient-enhanced
1H/
13C heteronuclear correla-
tion spectra (
13C-HSQC) [56] were acquired with a
1H spectral
width of 9600 Hz and 2048 complex points, zero-filled to a total of
4096. In the
13C dimension, with a spectral width of 21300 Hz, 96
hypercomplex increments were collected and linear predicted to a
total of 384 points. Gaussian and exponential weighting functions
were applied in the F2 dimension, while the indirectly detected
dimensions were Gaussian weighted only. Spectra were processed
in VnmrJH. Proton chemical shifts were referenced to DSS at
0.00 ppm. The carbon dimension was referenced indirectly by
taking into account the difference in the gyromagnetic ratios of
13C and
1H. NMR Spectroscopic Data for GABA:
1H NMR
(599.9 MHz, DSS, 30uC): d N 1.80 (Hb), 2.19 (Ha), 2.92 (Hc);
13C
NMR (125.8 MHz, DSS, 30uC): d N 23.9 (Cb), 34.8 (Ca), 39.7 (Cc).
Semicarbazide treatment
In experiments where semicarbazide (SCB) was applied,
animals were treated with SCB 3 hours before decapitation in
100 mg/kg dose intraperitoneally. During the experiments on
NPMV fractions and acute hippocampal slices SCB was present in
2 mM concentration. Efficiency of SCB treatment was confirmed
by the lack of [
13C]GABA formation in rat cortical NPMV
fraction (Figure 5A) and the reduced [
13C]GABA formation in
acute hippocampal slices (data not shown) following exposure of
preparations from treated animals to [
13C]Glu. Efficiency of SCB
treatment was also justified by the clear signs of epileptic seizures
induced in treated juvenile rats used for radiotracer release
experiments.
Statistics
Unless stated otherwise data are expressed as means6S.D. and
were analyzed using paired t-test or one-way analysis of variances
(ANOVA, OriginPro 7.5). A value of P,0.05 was considered
significant.
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